Eligible patients can now begin Leqembi treatment at home, potentially reducing repeated infusion-center visits while preserving essential medical supervision and safety monitoring.
COCHRANE SERIES, PART 3 – DEEP DIVE: False alarm. The Cochrane Review shook confidence in Leqembi. It rests on a scientific threshold its own source publicly disowned. Here’s why the evidence did not justify the alarm.
COCHRANE SERIES, PART 2 – HOW IT HAPPENED: A new review just went viral in the media, declaring Alzheimer’s drugs don’t work. Leading scientists say the methodology was fundamentally flawed.
COCHRANE SERIES, PART 1 – WHAT HAPPENED:
A respected review called a breakthrough Alzheimer’s drug useless. Experts shrugged. Investors, who normally panic on such news, barely noticed. Here’s why that matters — and what it means for families weighing their options.
In a new deal with Alloy Therapeutics, Biogen—the makers of Leqembi—is investing in RNA technology that could point toward what comes next in Alzheimer’s care.
Could Leqembi be given faster and more easily in the future? The new Biogen–Alteogen deal suggests it’s possible—but it doesn’t confirm changes to Leqembi. Here’s what professionals and families should understand.
The diagnostic and treatment network behind Leqembi may be its biggest competitive edge.
New research reveals that Leqembi’s Fc region switches on microglia — the brain’s immune cells — helping them clear toxic amyloid. Here’s why that mechanism matters for treatment and safety.
A safer Alzheimer’s treatment may be on the horizon — but families still have meaningful choices today.
Many diagnosed patients won’t qualify — here are the
7 medical criteria.
DIET RESEARCH: Learn how diet, exercise and watching your weight will prevent insulin-resistance, and as a result, protect your brain.
Memory is particularly vulnerable to the effects of insulin resistance, according to a 20-year study.
See joy shine in Mum, 87, despite Alzheimer’s, as her family transforms their home into Mum’s supermarket, stocked with grocery favorites.
J147 is a derivative of curry’s turmeric spice. It beat the Alzheimer’s drug Aricept (generic: donepezil) on several memory tests. The Salk Institute says it may benefit Parkinson’s, Huntington’s & vascular dementia.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
